JUN 17, 2020 9:47 PM PDT

Treating Atherosclerosis

WRITTEN BY: Nouran Amin

The two main proponents for atherosclerotic plaque and inflammation is an increase in cholesterol and macrophage presence in the arteries. Researchers at KAIST discuss that there designed physicochemical cargo-switching nanoparticles (CSNP) can address these issues.

What is atherosclerosis? A chronic inflammatory condition that targets the vasculature and characterized by the cholesterol and macrophage accumulation forming plaques in the arteries. If the atherosclerosis condition worsens, it may lead to heart attacks and strokes and potentially death.

Using the CSNP therapy, two drugs can be delivered at the same time. These drugs, cyclodextrin and statin, were proven to promote cholesterol-lowering, anti-inflammatory, and anti-proliferative functions. The therapeutic partnership of cyclodextrin and statin resolves the inflammatory environment of atherosclerosis.

"While nanomedicine has been mainly developed for the treatment of cancers, our studies show that nanomedicine can also play a significant role in treating and preventing atherosclerosis, which causes various cardiovascular diseases that are the leading causes of death worldwide, adds Professor Ji-Ho Park from KAIST’s Department of Bio and Brain Engineering.

Source: Science Daily

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 30, 2022
Neuroscience
Study Shows a High Rate of Negative Effects of Ayahuasca
Study Shows a High Rate of Negative Effects of Ayahuasca
A new study published in PLOS Global Public Health found a high rate of adverse physical and psychological effects from ...
DEC 16, 2022
Drug Discovery & Development
The Age of mRNA Cancer Vaccines Starts with Melanoma
The Age of mRNA Cancer Vaccines Starts with Melanoma
Earlier this week, pharmaceuticals Merck and Moderna announced “the first demonstration of efficacy” for an ...
DEC 17, 2022
Health & Medicine
A Universal Antidote for Drug Overdoses is in Development
A Universal Antidote for Drug Overdoses is in Development
Drug overdose deaths continue to rise in the United States. About 92,000 people died from drug and prescription opi ...
DEC 19, 2022
Cancer
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
TIL Therapy for Advanced Melanoma Extends Survival Over Ipilimumab
Immune checkpoint inhibitors (ICIs) have become a treatment option for many patients with advanced melanoma.  Still ...
JAN 04, 2023
Clinical & Molecular DX
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Scientists have developed a new, targeted strategy to eliminate brain tumors and prevent future recurrences of brain can ...
JAN 13, 2023
Drug Discovery & Development
Developing the First and Only Peptide-Formulated Neuromodulator for Wrinkles
Developing the First and Only Peptide-Formulated Neuromodulator for Wrinkles
In a wrinkle-reduction market run by AbbVie’s Botox™ (active ingredient onabotulinumtoxinA), Revance was jus ...
Loading Comments...